An analysis of pharmaceutical sales in the past decade shows how drugmakers have shifted their research focus from small molecules toward biotechnology products, according to a study from the Tufts Center for the Study of Drug Development. Biotech products accounted for 7% of revenue of the top 10 selling drugs globally in 2001 but 71% in 2012. The number of biologic drugs under clinical development grew to 907 last year from 355 in 2001, while biotech research funding surged from $10.5 billion to $103 billion. The change has been driven by the emergence of new drug development technologies and shorter patents of small-molecule drugs, said center director Kenneth Kaitin.
Published in Brief: